CAS: 1448584-12-0; (S)-N-(4-Hydroxyphenyl)-3-(6-(3-(Morpholinomethyl)-1,2,3,4-Tetrahydroisoquinoline-2-Carbonyl)Benzo[d][1,3]Dioxol-5-yl)-N-Phenyl-5,6,7,8-Tetrahydroindolizine-1-Carboxamide
- 英文名称(S)-N-(4-Hydroxyphenyl)-3-(6-(3-(Morpholinomethyl)-1,2,3,4-Tetrahydroisoquinoline-2-Carbonyl)Benzo[d][1,3]Dioxol-5-yl)-N-Phenyl-5,6,7,8-Tetrahydroindolizine-1-Carboxamide
- 中文名称(S)-N-(4-羟基苯基)-3-(6-(3-(吗啉甲基)-1,2,3,4-四氢异喹啉-2-羰基)苯甲酸[D][1,3]D-5-基)-N-苯基-5,6,7,8-四氢中氮茚-1-甲酰胺
- IUPAC名称(S)-N-(4-hydroxyphenyl)-3-(6-(3-(morpholinomethyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)benzo[d][1,3]dioxol-5-yl)-N-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide
- CAS编号1448584-12-0
- MFCD编号:MFCD31715456
- 分子式:C43H42N4O6分子量:710.83
- 产品CID: 683758
- 产品分类Inhibitors/Agonists → Apoptosis → Bcl-2
物理性质
合成工艺路线路线简述
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Pierrillas PB, Henin E, Ogier J, Kraus-Berthier L, Chenel M, Bouzom F, Tod M. Tumor Growth Inhibition Modelling Based on Receptor Occupancy and Biomarker Activity of a New Bcl-2 Inhibitor in Mice. J Pharmacol Exp Ther. 2018 Dec;367(3):414-424. doi: 10.1124/jpet.118.251694. Epub 2018 Sep 18. 47(6):648-656. doi: 10.1124/dmd.118.085605. Epub 2019 Apr 2. 4(5):8892-8906. doi: 10.1021/acsomega.9b00611.
4: Pierrillas PB, Henin E, Ogier J, Amiel M, Kraus-Berthier L, Chenel M, Bouzom F, Tod M. Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolation. Invest New Drugs. 2020 Dec;38(6):1796-1806. doi: 10.1007/s10637-020-00953-y. Epub 2020 May 25.
📝 需求与反馈
尽可能描述清楚需求与问题信息
